1
|
Silhol R, Maheu-Giroux M, Soni N, Simo Fotso A, Rouveau N, Vautier A, Doumenc-Aïdara C, Geoffroy O, N'Guessan KN, Sidibé Y, Kabemba OK, Gueye PA, Ndeye PD, Mukandavire C, Vickerman P, Keita A, Ndour CT, Larmarange J, Boily MC. Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis. Lancet HIV 2024; 11:e531-e541. [PMID: 38991596 DOI: 10.1016/s2352-3018(24)00126-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Revised: 04/24/2024] [Accepted: 05/07/2024] [Indexed: 07/13/2024]
Abstract
BACKGROUND During 2019-21, the AutoTest VIH, Libre d'accéder à la connaissance de son Statut (ATLAS) programme distributed around 380 000 HIV self-testing kits to key populations, including female sex workers, men who have sex with men, and their partners, in Côte d'Ivoire, Mali, and Senegal. We aimed to estimate the effects of the ATLAS programme and national scale-up of HIV self-test distribution on HIV diagnosis, HIV treatment coverage, HIV incidence, and HIV-related mortality. METHODS We adapted a deterministic compartmental model of HIV transmission in Côte d'Ivoire, parameterised and fitted to country-specific demographic, behavioural, HIV epidemiological, and intervention data in Côte d'Ivoire, Mali, and Senegal separately during 1980-2020. We simulated dynamics of new HIV infections, HIV diagnoses, and HIV-related deaths within scenarios with and without HIV self-test distribution among key populations. Models were separately parameterised and fitted to country-specific sets of epidemiological and intervention outcomes (stratified by sex, risk, age group, and HIV status, if available) over time within a Bayesian framework. We estimated the effects on the absolute increase in the proportion of people with HIV diagnosed at the end of 2021 for the ATLAS-only scenario and at the end of 2028 and 2038 for the HIV self-testing scale-up scenario. We estimated cumulative numbers of additional HIV diagnoses and initiations of antiretroviral therapy and the proportion and absolute numbers of new HIV infections and HIV-related deaths averted during 2019-21 and 2019-28 for the ATLAS-only scenario and during 2019-28 and 2019-38 for the HIV self-testing scale-up scenario. FINDINGS Our model estimated that ATLAS could have led to 700 (90% uncertainty interval [UI] 500-900) additional HIV diagnoses in Côte d'Ivoire, 500 (300-900) in Mali, and 300 (50-700) in Senegal during 2019-21, a 0·4 percentage point (90% UI 0·3-0·5) increase overall by the end of 2021. During 2019-28, ATLAS was estimated to avert 1900 (90% UI 1300-2700) new HIV infections and 600 (400-800) HIV-related deaths across the three countries, of which 38·6% (90% UI 31·8-48·3) of new infections and 70·1% (60·4-77·3) of HIV-related deaths would be among key populations. ATLAS would avert 1·5% (0·8-3·1) of all HIV-related deaths across the three countries during this period. Scaling up HIV self-testing would avert 16·2% (90% UI 10·0-23·1) of all new HIV infections during 2019-28 in Senegal, 5·3% (3·0-8·9) in Mali, and 1·6% (1·0-2·4) in Côte d'Ivoire. HIV self-testing scale-up among key populations was estimated to increase HIV diagnosis by the end of 2028 to 1·3 percentage points (90% UI 0·8-1·9) in Côte d'Ivoire, 10·6 percentage points (5·3-16·8) in Senegal, and 3·6 percentage points (2·0-6·4) in Mali. INTERPRETATION Scaling up HIV self-test distribution among key populations in western Africa could attenuate disparities in access to HIV testing and reduce infections and deaths among key populations and their partners. FUNDING Unitaid, Solthis, the UK Medical Research Council Centre for Global Infectious Disease Analysis, the EU European & Developing Countries Clinical Trials Partnership programme, and the Wellcome Trust. TRANSLATION For the French translation of the abstract see Supplementary Materials section.
Collapse
Affiliation(s)
- Romain Silhol
- Medical Research Council Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK.
| | - Mathieu Maheu-Giroux
- Department of Epidemiology and Biostatistics, School of Population and Global Health, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada
| | - Nirali Soni
- Medical Research Council Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
| | - Arlette Simo Fotso
- Centre Population et Développement, Université Paris Cité, Institut de Recherche pour le Développement, Institut National de la Santé et de la Recherche Médicale, Paris, France; French Institute for Demographic Studies, Institut National d'Études Démographiques, Paris, France
| | - Nicolas Rouveau
- Centre Population et Développement, Université Paris Cité, Institut de Recherche pour le Développement, Institut National de la Santé et de la Recherche Médicale, Paris, France
| | - Anthony Vautier
- Solidarité Thérapeutique et Initiatives pour la Santé, Solthis, Dakar, Senegal
| | | | - Olivier Geoffroy
- Solidarité Thérapeutique et Initiatives pour la Santé, Solthis, Abidjan, Côte d'Ivoire
| | | | - Younoussa Sidibé
- Solidarité Thérapeutique et Initiatives pour la Santé, Solthis, Bamako, Mali
| | - Odé Kanku Kabemba
- Solidarité Thérapeutique et Initiatives pour la Santé, Solthis, Bamako, Mali
| | - Papa Alioune Gueye
- Solidarité Thérapeutique et Initiatives pour la Santé, Solthis, Dakar, Senegal
| | - Pauline Dama Ndeye
- Solidarité Thérapeutique et Initiatives pour la Santé, Solthis, Dakar, Senegal
| | - Christinah Mukandavire
- Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
| | - Peter Vickerman
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | | | - Cheikh Tidiane Ndour
- Division de Lutte contre le Sida et les Infections Sexuellement Transmissibles, Ministère de la Santé et de l'Action Sociale Institut d'Hygiène Sociale, Dakar, Senegal
| | - Joseph Larmarange
- Centre Population et Développement, Université Paris Cité, Institut de Recherche pour le Développement, Institut National de la Santé et de la Recherche Médicale, Paris, France; French Institute for Demographic Studies, Institut National d'Études Démographiques, Paris, France
| | - Marie-Claude Boily
- Medical Research Council Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
| |
Collapse
|
2
|
Lu IJ, Silhol R, d'Elbée M, Boily M, Soni N, Ky‐Zerbo O, Vautier A, Simo Fosto A, Badiane K, Traoré M, Terris‐Prestholt F, Larmarange J, Maheu‐Giroux M. Cost-effectiveness analysis of community-led HIV self-testing among key populations in Côte d'Ivoire, Mali, and Senegal. J Int AIDS Soc 2024; 27:e26334. [PMID: 39034541 PMCID: PMC11260876 DOI: 10.1002/jia2.26334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 06/27/2024] [Indexed: 07/23/2024] Open
Abstract
INTRODUCTION HIV self-testing (HIVST) is a promising strategy to improve diagnosis coverage among key populations (KP). The ATLAS (Auto Test VIH, Libre d'Accéder à la connaissance de son Statut) programme implemented HIVST in three West African countries, distributing over 380,000 kits up between 2019 and 2021, focussing on community-led distribution by KP to their peers and subsequent secondary distribution to their partners and clients. We aim to evaluate the cost-effectiveness of community-led HIVST in Côte d'Ivoire, Mali and Senegal. METHODS An HIV transmission dynamics model was adapted and calibrated to country-specific epidemiological data and used to predict the impact of HIVST. We considered the distribution of HIVST among two KP-female sex workers (FSW), and men who have sex with men (MSM)-and their sexual partners and clients. We compared the cost-effectiveness of two scenarios against a counterfactual without HIVST over a 20-year horizon (2019-2039). The ATLAS-only scenario mimicked the 2-year implemented ATLAS programme, whereas the ATLAS-scale-up scenario achieved 95% coverage of HIVST distribution among FSW and MSM by 2025 onwards. The primary outcome is the number of disability-adjusted life-years (DALY) averted. Scenarios were compared using incremental cost-effectiveness ratios (ICERs). Costing was performed using a healthcare provider's perspective. Costs were discounted at 4%, converted to $USD 2022 and estimated using a cost-function to accommodate economies of scale. RESULTS The ATLAS-only scenario was highly cost-effective over 20 years, even at low willingness-to-pay thresholds. The median ICERs were $126 ($88-$210) per DALY averted in Côte d'Ivoire, $92 ($88-$210) in Mali and 27$ ($88-$210) in Senegal. Scaling-up the ATLAS programme would also be cost-effective, and substantial epidemiological impacts would be achieved. The ICERs for the scale-up scenario were $199 ($122-$338) per DALY averted in Côte d'Ivoire, $224 ($118-$415) in Mali and $61 ($18-$128) in Senegal. CONCLUSIONS Both the implemented and the potential scale-up of community-led HIVST programmes in West Africa, where KP are important to overall transmission dynamics, have the potential to be highly cost-effective, as compared to a scenario without HIVST. These findings support the scale-up of community-led HIVST to reach populations that otherwise may not access conventional testing services.
Collapse
Affiliation(s)
- Ingrid Jiayin Lu
- Department of Epidemiology and BiostatisticsSchool of Population and Global HealthFaculty of Medicine and Health SciencesMcGill UniversityMontréalQuébecCanada
| | - Romain Silhol
- Medical Research Council Centre for Global Infectious Disease AnalysisImperial College LondonLondonUK
| | - Marc d'Elbée
- University of BordeauxNational Institute for Health and Medical Research (INSERM) UMR 1219Research Institute for Sustainable Development (IRD) EMR 271Bordeaux Population Health CentreBordeauxFrance
- CepedUniversité Paris CitéIRDInsermParisFrance
| | - Marie‐Claude Boily
- Medical Research Council Centre for Global Infectious Disease AnalysisImperial College LondonLondonUK
| | - Nirali Soni
- Medical Research Council Centre for Global Infectious Disease AnalysisImperial College LondonLondonUK
| | - Odette Ky‐Zerbo
- TransVIHMIUniversité de MontpellierIRDINSERMMontpellierFrance
| | | | - Artlette Simo Fosto
- L'Institut national d’études démographiques (INED)AubervilliersFrance
- Ceped UMR 196, Université Paris CitéResearch Institute for Sustainable Development (IRD)InsermParisFrance
| | | | - Metogara Traoré
- Université LavalQuébec CityQuébecCanada
- VITAM ‐ Centre de recherche en santé durableQuébec CityQuébecCanada
- Centre de recherche du CHU de QuébecQuébec CityQuébecCanada
| | | | | | - Mathieu Maheu‐Giroux
- Department of Epidemiology and BiostatisticsSchool of Population and Global HealthFaculty of Medicine and Health SciencesMcGill UniversityMontréalQuébecCanada
| | | |
Collapse
|
3
|
Allorant A, Muset P, Hodgins C, Kirakoya-Samadoulougou F, Namachapa K, Mbofana F, Panagiotoglou D, Johnson LF, Imai-Eaton JW, Maheu-Giroux M. Temporal Trends and Determinants of HIV Testing at Antenatal Care in Sub-Saharan Africa: A Pooled Analysis of Population-Based Surveys (2005-2021). J Acquir Immune Defic Syndr 2024; 95:e97-e105. [PMID: 38180847 PMCID: PMC10769174 DOI: 10.1097/qai.0000000000003329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2024]
Abstract
BACKGROUND In sub-Saharan Africa (SSA), integrating HIV testing into antenatal care (ANC) has been crucial toward reducing mother-to-child transmission of HIV. With the introduction of new testing modalities, we explored temporal trends in HIV testing within and outside of ANC and identified sociodemographic determinants of testing during ANC. METHODS We analyzed data from 139 nationally representative household surveys conducted between 2005 and 2021, including more than 2.2 million women aged 15-49 years in 41 SSA countries. We extracted data on women's recent HIV testing history (<24 months), by modality (ie, at ANC versus outside of ANC) and sociodemographic variables (ie, age, socioeconomic status, education level, number of births, urban/rural). We used Bayesian generalized linear mixed models to estimate HIV testing coverage and the proportion of those that tested as part of ANC. RESULTS HIV testing coverage (<24 months) increased substantially between 2005 and 2021 from 8% to 38%, with significant variations between countries and subregions. Two percent of women received an HIV test in the 24 months preceding the survey interview as part of ANC in 2005 and 11% in 2021. Among women who received an HIV test in the 24 months preceding the survey, the probability of testing at ANC was significantly greater for multiparous, adolescent girls, rural women, women in the poorest wealth quintile, and women in West and Central Africa. CONCLUSION ANC testing remains an important component to achieving high levels of HIV testing coverage and benefits otherwise underserved women, which could prove instrumental to progress toward universal knowledge of HIV status in SSA.
Collapse
Affiliation(s)
- Adrien Allorant
- Department of Epidemiology and Biostatistics, School of Global and Population Health, McGill University, Montréal, Canada
| | - Paul Muset
- Department of Epidemiology and Biostatistics, School of Global and Population Health, McGill University, Montréal, Canada
| | - Caroline Hodgins
- Department of Epidemiology and Biostatistics, School of Global and Population Health, McGill University, Montréal, Canada
| | - Fati Kirakoya-Samadoulougou
- Research Center in Epidemiology, Biostatistics, and Clinical Research, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium
| | - Khumbo Namachapa
- Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi
| | - Francisco Mbofana
- Conselho Nacional de Combate ao SIDA, Ministry of Health, Maputo, Mozambique
| | - Dimitra Panagiotoglou
- Department of Epidemiology and Biostatistics, School of Global and Population Health, McGill University, Montréal, Canada
| | - Leigh F. Johnson
- Centre for Infectious Disease Epidemiology and Research, University of Cape Town, City of Cape Town, WC, South Africa
| | - Jeffrey W. Imai-Eaton
- Department of Epidemiology, Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, MA; and
- MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom
| | - Mathieu Maheu-Giroux
- Department of Epidemiology and Biostatistics, School of Global and Population Health, McGill University, Montréal, Canada
| |
Collapse
|
4
|
Kra AK, Fotso AS, N’guessan KN, Geoffroy O, Younoussa S, Kabemba OK, Gueye PA, Ndeye PD, Rouveau N, Boily MC, Silhol R, d’Elbée M, Maheu-Giroux M, Vautier A, Larmarange J. Can HIV self-testing reach first-time testers? A telephone survey among self-test end users in Côte d'Ivoire, Mali, and Senegal. BMC Infect Dis 2023; 22:972. [PMID: 37749490 PMCID: PMC10518917 DOI: 10.1186/s12879-023-08626-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Accepted: 09/18/2023] [Indexed: 09/27/2023] Open
Abstract
BACKGROUND Coverage of HIV testing remains sub-optimal in West Africa. Between 2019 and 2022, the ATLAS program distributed ~400 000 oral HIV self-tests (HIVST) in Côte d'Ivoire, Mali, and Senegal, prioritising female sex workers (FSW) and men having sex with men (MSM), and relying on secondary redistribution of HIVST to partners, peers and clients to reach individuals not tested through conventional testing. This study assesses the proportion of first-time testers among HIVST users and the associated factors. METHODS A phone-based survey was implemented among HIVST users recruited using dedicated leaflets inviting them to anonymously call a free phone number. We collected socio-demographics, sexual behaviours, HIV testing history, HIVST use, and satisfaction with HIVST. We reported the proportion of first-time testers and computed associated factors using logistic regression. RESULTS Between March and June 2021, 2 615 participants were recruited for 50 940 distributed HIVST (participation rate: 5.1%). Among participants, 30% received their HIVST kit through secondary distribution (from a friend, sexual partner, family member, or colleague). The proportion who had never tested for HIV before HIVST (first-time testers) was 41%. The main factors associated with being a first-time tester were sex, age group, education level, condom use, and secondary distribution. A higher proportion was observed among those aged 24 years or less (55% vs 32% for 25-34, aOR: 0.37 [95%CI: 0.30-0.44], and 26% for 35 years or more, aOR: 0.28 [0.21-0.37]); those less educated (48% for none/primary education vs 45% for secondary education, aOR: 0.60 [0.47-0.77], and 29% for higher education, aOR: 0.33 [0.25-0.44]). A lower proportion was observed among women (37% vs 43%, aOR: 0.49 [0.40-0.60]); those reporting always using a condom over the last year (36% vs 51% for those reporting never using them, aOR: 2.02 [1.59-2.56]); and those who received their HISVST kit through primary distribution (39% vs 46% for secondary distribution, aOR: 1.32 [1.08-1.60]). CONCLUSION ATLAS HIVST strategy, including secondary distribution, successfully reached a significant proportion of first-time testers. HIVST has the potential to reach underserved populations and contribute to the expansion of HIV testing services in West Africa.
Collapse
Affiliation(s)
- Arsène Kouassi Kra
- Centre Population et Développement (Ceped), Institut de Recherche pour le Développement (IRD), Université Paris Cité, Inserm, Paris, France
| | - Arlette Simo Fotso
- Centre Population et Développement (Ceped), Institut de Recherche pour le Développement (IRD), Université Paris Cité, Inserm, Paris, France
- Institut National d’Etudes Démographiques (INED), Aubervilliers, France
| | | | - Olivier Geoffroy
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Abidjan, Côte d’Ivoire
| | - Sidibé Younoussa
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Bamako, Mali
| | - Odé Kanku Kabemba
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Bamako, Mali
| | - Papa Alioune Gueye
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Dakar, Sénégal
| | - Pauline Dama Ndeye
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Dakar, Sénégal
| | - Nicolas Rouveau
- Centre Population et Développement (Ceped), Institut de Recherche pour le Développement (IRD), Université Paris Cité, Inserm, Paris, France
| | - Marie-Claude Boily
- MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
| | - Romain Silhol
- MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
| | - Marc d’Elbée
- Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
- National Institute for Health and Medical Research UMR 1219, Research Institute for Sustainable Development EMR 271, Bordeaux Population Health Centre, University of Bordeaux, Bordeaux, France
| | - Mathieu Maheu-Giroux
- Department of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, QC H3A 1A2 Canada
| | - Anthony Vautier
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Dakar, Sénégal
| | - Joseph Larmarange
- Centre Population et Développement (Ceped), Institut de Recherche pour le Développement (IRD), Université Paris Cité, Inserm, Paris, France
| | - on behalf of the ATLAS team
- Centre Population et Développement (Ceped), Institut de Recherche pour le Développement (IRD), Université Paris Cité, Inserm, Paris, France
- Institut National d’Etudes Démographiques (INED), Aubervilliers, France
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Abidjan, Côte d’Ivoire
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Bamako, Mali
- Solidarité Thérapeutique et Initiatives pour la Santé (Solthis), Dakar, Sénégal
- MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
- Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
- National Institute for Health and Medical Research UMR 1219, Research Institute for Sustainable Development EMR 271, Bordeaux Population Health Centre, University of Bordeaux, Bordeaux, France
- Department of Epidemiology and Biostatistics, School of Population and Global Health, McGill University, Montréal, QC H3A 1A2 Canada
| |
Collapse
|
5
|
Grimsrud A, Wilkinson L, Ehrenkranz P, Behel S, Chidarikire T, Chisenga T, Golin R, Johnson CC, Milanga M, Onyekwena O, Sundaram M, Wong V, Baggaley R. The future of HIV testing in eastern and southern Africa: Broader scope, targeted services. PLoS Med 2023; 20:e1004182. [PMID: 36917570 PMCID: PMC10013883 DOI: 10.1371/journal.pmed.1004182] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
Abstract
In this Policy Forum, Anna Grimsrud and colleagues discuss the future of HIV testing in eastern and southern Africa, using insights gleaned from a 2021 expert consultation.
Collapse
Affiliation(s)
- Anna Grimsrud
- IAS–International AIDS Society, Cape Town, Western Cape, South Africa
| | - Lynne Wilkinson
- IAS–International AIDS Society, Cape Town, Western Cape, South Africa
- University of Cape Town, Cape Town, South Africa
| | - Peter Ehrenkranz
- Bill & Melinda Gates Foundation, Seattle, Washington, United States of America
| | - Stephanie Behel
- Centres for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - Thato Chidarikire
- South Africa National Department of Health, Pretoria, Gauteng, South Africa
| | | | - Rachel Golin
- Office of the Global AIDS Coordinator and Health Diplomacy, Washington DC, United States of America
- United States Agency for International Development, Washington DC, United States of America
| | | | | | | | - Maaya Sundaram
- Bill & Melinda Gates Foundation, Seattle, Washington, United States of America
| | - Vincent Wong
- United States Agency for International Development, Washington DC, United States of America
| | | |
Collapse
|